Menagen exclusively licenses MENAT rights to L606, an inhaled formulation of treprostinil administered twice daily with a short-duration, next-generation nebulizer
Menagens focus is to facilitate localization and access to innovative medicines for patients in need within the MENAT region through a diversified portfolio to cover multiple unmet needs of different illnesses
Pharmosa to receive upfront and milestone payments and royalties from Menagen
Pharmosa will supply the commercial products with the ratio of high two figure of the end user price to Menagen
Menagen and Pharmosa Biopharm Inc. (Pharmosa) announced that they have entered into an exclusive licensing agreement for commercialization in the MENAT region of L606, an inhaled, sustained-release formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Saif Al Hasani, Chief Executive Officer of Menagen, stated:
“L606 is the perfect life-cycle complement to our pipeline and furthers our mission to provide innovative treatment options that improve the lives of rare disease and unmet medical disease patients suffering from PAH or PH-ILD.
As already observed in the study of PAH patients, Pharmosa’s novel liposomal formulation offers the potential to improve patients’ convenience and compliance with twice-daily dosing using a short-duration, next-generation nebulizer.
More importantly, we believe that the inhaled drug-device combination may provide best-in-class treprostinil exposure over a 24-hour period, including during sleeping hours, which could translate to improved efficacy, tolerability, and patient outcomes.
Our investment in this collaboration, alongside our continued preparation for other potential launches of multiple products, are clear examples of Menagen’s commitment to addressing unmet needs in treating rare and critical diseases.”
Pei Kan, Ph.D., President of Pharmosa, added:
“Menagen is the ideal partner to bring L606 to the MENAT region markets. Menagen has shown an unflinching determination to bring novel products to patients and provides clear synergies with their commercial effort, clinical expertise, and deep relationships with key opinion leaders.
Pharmosa will focus on advancing its sustained-release liposomal technology, which has demonstrated in L606 the ability to dramatically reduce maximum systemic drug concentrations while significantly increasing local concentrations deep in the lung.”
Under the agreement, Pharmosa will be responsible for the commercial supply of L606 products to Menagen, and Menagen will be responsible for local production, regulatory and commercial activities of L606 within the MENAT region.
About L606 (liposomal treprostinil) inhalation suspension
L606 is a liposomal formulation of treprostinil administered twice daily with a short-duration, next-generation nebulizer. The L606 suspension uses Pharmosa’s proprietary liposomal formulation to encapsulate treprostinil, which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period and reducing local irritation of the upper respiratory tract.
L606 is currently being evaluated in an open-label study in the United States for the treatment of pulmonary arterial hypertension (PAH) with a planned pivotal study for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
About Menagen
Menagen is a biopharmaceutical company developing innovative and biosimilar medicines in the MENAT region, with its headquarters in Muscat, Oman.
The company focuses on producing and commercializing multiple innovative medicines by partnering/in-licensing with international companies to facilitate access to patients within the MENAT region. Menagen’s portfolio addresses unmet needs in various disease areas, including rare diseases, oncology/hematology, respiratory, cardiovascular, and consumer health care.
About Pharmosa Biopharm
Pharmosa Biopharm Inc. (PBI) is a Taiwan-based biotechnology company focused on developing new drugs by exploiting its proprietary liposomal formulations and manufacturing technology. With regional and global strategic partnerships, PBI develops products through 505(b)(2) or hybrid applications to regulatory authorities with the intent to expand the clinical potential of existing drugs by exploiting innovative delivery formulations and medical devices.
